# NCT06711900 (NCT06711900)

> A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06711900
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Non-Small Cell Lung Cancer
- Interventions: SKB264; Pembrolizumab; pemetrexed; carboplatin or cisplatin
- Enrollment: 432
- Primary outcome: Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06711900

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06711900", "email": "<work email>"}; the inbox owner confirms by the emailed link.